Abstract
CS-866 is a new angiotensin II receptor blocker that has demonstrated effectiveness for lowering blood pressure in animal models of hypertension. Given the proposed involvement of the renin-angiotensin system in diabetic nephropathy and atherosclerosis, we have tested CS-866 in animal models of these conditions. The renal protective properties of CS-866 were examined in the Zucker diabetic fatty (ZDF) rat, a model of type 2 diabetes that develops progressive hyperglycemia, glomerulosclerosis, and proteinuria. Treatment of ZDF rats with CS-866 in the diet for 19 weeks resulted in a dose-dependent reduction in urinary protein excretion compared with vehicle-treated control rats, which was independent of changes in blood pressure and glycemic state. The antiatherosclerotic properties of CS-866 were tested in 2 animal models. In the first study, cynomolgus monkeys were fed a high-cholesterol diet for 6 months while receiving CS-866 or vehicle. At the end of this period, CS-866-treated animals had 64% less plaque area in the aorta than controls. CS-866 was also tested in the Watanabe heritable hyperlipidemic (WHHL) rabbit model of atherosclerosis. WHHL rabbits were treated for 32 weeks with CS-866 (1 mg/kg), pravastatin (50 mg/kg), ...Continue Reading
References
Mar 1, 1990·Hypertension·A V ChobanianR Drago
Apr 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·T KitaJ L Goldstein
Jun 1, 1994·The Journal of Clinical Investigation·S KagamiN A Noble
Oct 16, 1995·European Journal of Pharmacology·M MizunoH Koike
Jan 5, 1996·Journal of Medicinal Chemistry·H YanagisawaH Koike
Jun 20, 1996·The New England Journal of Medicine·T L GoodfriendK J Catt
Jan 1, 1996·Journal of the American Society of Nephrology : JASN·J P VoraS Anderson
Sep 1, 1996·Journal of Cardiovascular Pharmacology·Z LiD I Diz
Mar 6, 1998·Journal of Hypertension·K PüchlerH R Brunner
Jul 25, 1998·Atherosclerosis·K SongM Miyazaki
Apr 20, 1999·Circulation·A WarnholtzT Münzel
May 15, 1999·Circulation Research·D Y LiJ L Mehta
Jan 5, 2000·Kidney International·T M CoimbraJ Floege
Jan 27, 2000·General Pharmacology·C NapoliG Cirino
Apr 4, 2000·Circulation·W B StrawnC M Ferrario
Sep 21, 2000·Kidney International. Supplement·D J LeeheyR Singh
Citations
Apr 25, 2009·Mediators of Inflammation·Fabrizio MontecuccoFrançois Mach
Feb 28, 2007·Vascular Health and Risk Management·Hans R Brunner
Sep 23, 2010·Vascular Health and Risk Management·Carlos M Ferrario, Ronald D Smith
May 5, 2011·Journal of Biomedicine & Biotechnology·Tsutomu KobayashiMasashi Shiomi
Jul 1, 2008·Future Cardiology·Christoph Schindler, Carlos M Ferrario
Aug 19, 2007·Life Sciences·G K AulakhM Singh
Nov 16, 2010·Biomedical Chromatography : BMC·Pinaki SenguptaTapan Kumar Pal
Jun 9, 2004·Life Sciences·Minoru SasakiHiroyoshi Matsumoto
Apr 21, 2005·European Journal of Pharmacology·Hiroaki NakamuraTomihisa Yokoyama
Oct 13, 2011·Drug Development and Industrial Pharmacy·Myung J KangYoung W Choi
Mar 12, 2004·Expert Opinion on Pharmacotherapy·Steven G Chrysant, George S Chrysant
Apr 3, 2007·Journal of the American College of Cardiology·Kumiko ArishiroToshiaki Hanafusa
May 31, 2002·Journal of Human Hypertension·S Oparil
Oct 7, 2004·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Toshio Sada, Makoto Mizuno
Jun 8, 2007·Journal of Human Hypertension·S G ChrysantM Shiraz
Nov 7, 2007·Journal of Hypertension·José W A van der HoornJ Wouter Jukema
Feb 6, 2003·Journal of Hypertension·Ulf de Faire
Oct 3, 2002·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Haruhiro TokoIssei Komuro
Oct 18, 2002·American Journal of Hypertension·Edmund J Lewis
Oct 18, 2002·American Journal of Hypertension·Ernesto L Schiffrin, UNKNOWN Canadian Institutes of Health Research Multidisciplinary Research Group on Hypertension
Dec 31, 2003·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S Jellinger, UNKNOWN FACE
Mar 17, 2004·The Journal of Toxicological Sciences·Seiya OgataSunao Manabe